HCM
HUTCHMED (China) Ltd
$10.63
-2.03%
$1.9B
No data for this timeframe.
Vol
Market Cap$1.9B
Cap SizeSmall Cap
Inst. Holders4 funds
Inst. Value$2.3M
Inst. Activity1 buys / 1 sells
Reddit Sentiment50° Neutral
Press Releases4
Recent Activity
May 20, 2026
Insider
Chiu Lorenso sold 5,176 shares
Deputy Chief Financial Officer @ $0.00 ($0.00)
May 20, 2026
Insider
Chiu Lorenso sold 8,863 shares
Deputy Chief Financial Officer @ $0.00 ($0.00)
May 20, 2026
Insider
Su Wei-guo sold 132,864 shares
CEO and CSO @ $0.00 ($0.00)
Inst.
UBS Group AG — DOUBLED
137,000 shares ($2.2M)
Inst.
TWO SIGMA INVESTMENTS, LP — EXIT
0 shares ($0.00)
May 22, 2026
routine
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
<p align="justify">HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (Ch
Apr 9, 2026
Press
HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibody-targeted therapy
Impact 6/10
Mar 23, 2026
Press
HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibitor, in combination w
Impact 7/10
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$22.91 (Mar 2026)
Current $10.63
Low $13.60
Median $20.64
High $40.40
14 analysts
$13.60
$40.40
Analyst Ratings
10Strong Buy
13Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 10, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $0.38 | $0.09 — $0.58 | -85% YoY | 5 |
| Next FY | $0.49 ▼ -5.0% | $0.13 — $0.93 | 28% YoY | 5 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $1.8M | TRIM |
| BANK OF AMERICA CORP | $282.4K | — |
| MORGAN STANLEY | $161.9K | TRIM |
| FMR LLC | $47.1K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Chiu Lorenso | J | $0.00 |
| May 20, 2026 | Chiu Lorenso | J | $0.00 |
| May 20, 2026 | Su Wei-guo | J | $0.00 |
| May 20, 2026 | Su Wei-guo | J | $0.00 |
| May 20, 2026 | Nixon Charles | J | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
4 institutional holders with $2.3M total value (171,761 shares) as of 2025-Q4. Top holders: RENAISSANCE, BANK, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 134,900 | $1.8M | 78.5% | TRIM -28.3% |
| 2 | BANK OF AMERICA CORP /DE/ | 21,183 | $282.4K | 12.3% | — |
| 3 | MORGAN STANLEY | 12,147 | $161.9K | 7.1% | TRIM -72.6% |
| 4 | FMR LLC | 3,531 | $47.1K | 2.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 64,386 | 137,000 | +112.8% | $2.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 27,641 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | TRIM | 216,565 | 64,386 | -70.3% | $969.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 47,262 | 27,641 | -41.5% | $416.0K | 2025-Q2 |
| UBS Group AG | TRIM | 377,728 | 216,565 | -42.7% | $3.3M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 188,539 | 135,200 | -28.3% | $2.0M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 53,857 | 24,605 | -54.3% | $370.1K | 2025-Q1 |
| UBS Group AG | DOUBLED | 103,638 | 377,728 | +264.5% | $5.4M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 25,189 | 53,857 | +113.8% | $776.1K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 96,791 | 26,511 | -72.6% | $382.0K | 2024-Q4 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Chiu Lorenso | Deputy Chief Financial Officer | J | 5,176 | $0.00 | $0.00 |
| May 20, 2026 | Chiu Lorenso | Deputy Chief Financial Officer | J | 8,863 | $0.00 | $0.00 |
| May 20, 2026 | Su Wei-guo | CEO and CSO | J | 132,864 | $0.00 | $0.00 |
| May 20, 2026 | Su Wei-guo | CEO and CSO | J | 75,140 | $0.00 | $0.00 |
| May 20, 2026 | Nixon Charles George Rupert | Group General Counsel | J | 7,445 | $0.00 | $0.00 |
| May 20, 2026 | Nixon Charles George Rupert | Group General Counsel | J | 7,644 | $0.00 | $0.00 |
| May 20, 2026 | Cheng Chig Fung | Acting CEO and CFO | J | 30,157 | $0.00 | $0.00 |
| May 20, 2026 | Cheng Chig Fung | Acting CEO and CFO | J | 26,307 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
MIXED
6/10
HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibo
Apr 9, 2026
BULLISH
7/10
HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibit
Mar 23, 2026
MIXED
6/10
HUTCHMED reported mixed financial results for 2025, with a significant $457 million net income drive
Mar 5, 2026
NEUTRAL
5/10
HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Ther
Mar 4, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 88% buy across 26 analysts — 10 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$22.91 mean target (Mar 2026)
$13.60 Low
$40.40 High
| Metric | Value |
|---|---|
| Current Price | $10.63 |
| Target Low | $13.60 |
| Target Mean | $22.91 |
| Target Median | $20.64 |
| Target High | $40.40 |
| # Analysts | 14 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.38 | $0.09 | $0.58 | -85.3% | +0.0% | 0↑ 2↓ | $0.6B | 17.0% | 5 |
| Next FY 2027-12-31 |
$0.49 | $0.13 | $0.93 | 28.5% | -5.0% | 0↑ 1↓ | $0.7B | 14.6% | 5 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 10, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 13 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Apr 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Mar 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| Feb 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| Jan 1, 2026 | 9 | 15 | 2 | 1 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 28, 2025 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Alternative Nuclear Plays To OKLO/SMR
▲ 13
💬 15
⚡ 0.0
May 22, 2026
routine
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
<p align="justify">HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www.globenewswire.
May 21, 2026
other
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study <pre>Reduced risk of disease p
Apr 9, 2026
fda
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 23, 2026
fda
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 9, 2026
other
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 6, 2026
other
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 5, 2026
earnings
HUTCHMED Reports 2025 Full Year Results and Business Updates
<p align="center"><em>— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth —</em></p>
Mar 4, 2026
fda
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
<p align="center"><em>— Second clinical candidate from HUTCHMED’s next-generation ATTC platform —</em></p>